Increased conc w/ delavirdine, itraconazole, isavuconazole ketoconazole, posaconazole, voriconazole, simeprevir. Decreased exposure w/ lopinavir/ritonavir, saquinavir, systemic dexamethasone, boceprevir, telaprevir. Increased exposure w/ indinavir, rifabutin. Increased exposure of maraviroc, digoxin, lomitapide. Increased exposure to alfuzosin, ranolazine, amiodarone, bepridil, disopyramide, dronedarone, flecainide, mexiletine, propafenone, systemic lidocaine, quinidine, clarithromycin, colchicine, astemizole, terfenadine, lumefantrine, lurasidone, pimozide, risperidone, thioridazine, quetiapine, amlodipine, diltiazem, felodipine, nicardipine, nifedipine, verapamil, ergot alkaloids, cisapride, elbasvir/grazoprevir, ecaprevir/pibrentasvir, immunosuppressants. Increased plasma conc of apixaban, dabigatran, edoxaban, rivaroxaban, clonazepam, amitriptyline, desipramine, imipramine, nortriptyline, trazodone, clotrimazole, fluconazole, dasatinib, everolimus, irinotecan, nilotinib, vinblastine, vincristine, perphenazine, carvedilol, metoprolol, timolol, betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone, bosentan, HMG-CoA reductase inhibitors, fentanyl, oxycodone, tramadol, ticagrelor, sedatives/hypnotics. Decreased plasma conc w/ phenobarb, phenytoin, rifampin, rifapentine, St. John's wort. Decreased exposure to sertraline, paroxetine, artemether, ethinylestradiol, norethindrone. Potential of hyperkalemia w/ drospirenone-containing product. Increased risk of CV adverse events w/ salmeterol. Not recommended w/ PDE-5 inhibitors. Elvitegravir, ivabradine, warfarin, carbamazepine, domperidone, buprenorphine, methadone, naloxegol, sildenafil, tadalafil, dapoxetine, fesoterodine, solifenacin.
Sign Out
